Company News
Zymeworks Phase 1 Trial Shows 78.6% Response
Zymeworks presented Phase 1 data for ZW191 in platinum‑resistant ovarian and endometrial cancers at the ESMO Gyn 2026 Congress.
Confirmed objective response rate reached 78.6% in FRα‑positive tumors a
